Will there be a cure for Ebola?

Annual Review of Pharmacology and Toxicology

Volumn 57, Issue , 2017, Pages 329-348

  Cardile, Anthony P ^a   Warren, Travis K ^a   Martins, Karen A ^a   Reisler, Ronald B ^a   Bavari, Sina ^a  

^a UNITED STATES ARMY MEDICAL RESEARCH INSTITUTE OF INFECTIOUS DISEASES   (United States)

Author keywords

BCX4430; Brincidofovir; Convalescent plasma; Favipiravir; GS 5734; ZMapp

Indexed keywords

AVI 7537; BETA INTERFERON; BRINCIDOFOVIR; FAVIPIRAVIR; GALIDESIVIR; GS 5734; HYPERIMMUNE GLOBULIN; IMMUNOMODULATING AGENT; NUCLEOSIDE ANALOG; NUCLEOTIDE DERIVATIVE; TKM EBOLA; UNCLASSIFIED DRUG; ZMAPP; 2-(4-AMINO-5H-PYRROLO(3,2-D)PYRIMIDIN-7-YL)-5-(HYDROXYMETHYL)PYRROLIDINE-3,4-DIOL; ALANINE; ANTIVIRUS AGENT; GS-5734; PURINE NUCLEOSIDE; RIBONUCLEOTIDE;

AFRICA; CLINICAL RESEARCH; DRUG REPOSITIONING; EBOLA HEMORRHAGIC FEVER; EBOLAVIRUS; EPIDEMIC; FOOD AND DRUG ADMINISTRATION; HUMAN; MULTICENTER STUDY (TOPIC); NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; ANALOGS AND DERIVATIVES; ANIMAL; DRUG EFFECTS; PHYSIOLOGY;

AFRICA, WESTERN; ALANINE; ANIMALS; ANTIVIRAL AGENTS; DISEASE OUTBREAKS; EBOLAVIRUS; HEMORRHAGIC FEVER, EBOLA; HUMANS; PURINE NUCLEOSIDES; RIBONUCLEOTIDES;

EID: 85009110552     PISSN: 03621642     EISSN: 15454304     Source Type: Book Series    
DOI: 10.1146/annurev-pharmtox-010716-105055     Document Type: Review

References (108)

1. Merriam-Webster.com. 2016. Cure. Accessed on Mar. 1. http://www.merriam-webster.com/dictionary/cure
2. Greenwood B. 2014. The contribution of vaccination to global health: past, present and future. Philos. Trans. R. Soc. B 369:20130433
3. Mariner JC, House JA, Mebus CA, Sollod AE, Chibeu D, et al. 2012. Rinderpest eradication: appropriate technology and social innovations. Science 337:1309-12
4. Ohimain EI. 2016. Recent advances in the development of vaccines for Ebola virus disease. Virus Res. 211:174-85
5. Sridhar S. 2015. Clinical development of Ebola vaccines. Ther. Adv. Vaccines 3:125-38
6. WHO (World Health Organ.). 2015. Table of drug clinical trials. WHO, Geneva. Accessed on July http://www.who.int/medicines/ebola-treatment/ebola-drug-clinicaltrials/en/7.
7. Hensley LE, Dyall J, Olinger GG Jr., Jahrling PB. 2015. Lack of effect of lamivudine on Ebola virus replication. Emerg. Infect. Dis. 21:550-52
8. Fedson DS. 2015. Immunomodulatory adjunctive treatment options for Ebola virus disease patients: another view. Intensive Care Med. 41:1383
9. Fedson DS, Jacobson JR, RordamOM, Opal SM. 2015. Treating the host response to Ebola virus disease with generic statins and angiotensin receptor blockers. mBio 6:e00716
10. Fedson DS, Rordam OM. 2015. Treating Ebola patients: a 'bottom up' approach using generic statins and angiotensin receptor blockers. Int. J. Infect. Dis. 36:80-84
11. WHO (World Health Organ.). 2015. Categorization and prioritization of drugs for consideration for testing or use in patients infected with Ebola. News Release, Jan. 19. Accessed on July, http://www.who.int/medicines/ebola-treatment/cat-prioritization-drugs-testing/en/
12. Bavari S, Bosio CM, Wiegand E, Ruthel G,Will AB, et al. 2002. Lipid raft microdomains: a gateway for compartmentalized trafficking of Ebola and Marburg viruses. J. Exp. Med. 195:593-602
13. Bhattacharyya S, Warfield KL, Ruthel G, Bavari S, AmanMJ, Hope TJ. 2010. Ebola virus uses clathrinmediated endocytosis as an entry pathway. Virology 401:18-28
14. Madrid PB, Chopra S, Manger ID, Gilfillan L, Keepers TR, et al. 2013. A systematic screen of FDAapproved drugs for inhibitors of biological threat agents. PLOS ONE 8:e60579
15. Miller ME, Adhikary S, Kolokoltsov AA, Davey RA. 2012. Ebolavirus requires acid sphingomyelinase activity and plasma membrane sphingomyelin for infection. J. Virol. 86:7473-83
16. Sakurai Y, Kolokoltsov AA, Chen CC, TidwellMW, BautaWE, et al. 2015. Two-pore channels control Ebola virus host cell entry and are drug targets for disease treatment. Science 347:995-98
17. Yonezawa A, Cavrois M, Greene WC. 2005. Studies of Ebola virus glycoprotein-mediated entry and fusion by using pseudotyped human immunodeficiency virus type 1 virions: involvement of cytoskeletal proteins and enhancement by tumor necrosis factor alpha. J. Virol. 79:918-26
18. Cheng H, Lear-Rooney CM, Johansen L, Varhegyi E, Chen ZW, et al. 2015. Inhibition of Ebola and Marburg viral entry by G protein-coupled receptor antagonists. J. Virol. 89:9932-38
19. Johansen LM, DeWald LE, Shoemaker CJ, Hoffstrom BG, Lear-Rooney CM, et al. 2015. A screen of approved drugs and molecular probes identifies therapeutics with anti-Ebola virus activity. Sci. Trans. Med. 7:290ra89
20. Johansen LM, Brannan JM, Delos SE, Shoemaker CJ, Stossel A, et al. 2013. FDA-approved selective estrogen receptor modulators inhibit Ebola virus infection. Sci. Transl. Med. 5:190ra79
21. Gehring G, Rohrmann K, Atenchong N, Mittler E, Becker S, et al. 2014. The clinically approved drugs amiodarone, dronedarone and verapamil inhibit filovirus cell entry. J. Antimicrob. Chemother. 69:2123-31
22. Salata C, Baritussio A,Munegato D, Calistri A, Ha HR, et al. 2015. Amiodarone and metaboliteMDEA inhibit Ebola virus infection by interfering with the viral entry process. Pathog. Dis. 73: 32
23. Turone F. 2014. Doctors trial amiodarone for Ebola in Sierra Leone. BMJ 349:g7198
24. Makimoto H, Noda T, Kurita T, Nakajima I, Yokoyama T, et al. 2011. Incessant monomorphic ventricular tachycardia induced by the proarrhythmic effect of amiodarone. Intern. Med. 50:2591-95
25. Chow MS. 1996. Intravenous amiodarone: pharmacology, pharmacokinetics, and clinical use. Ann. Pharmacother. 30:637-43
26. Epstein AE, Olshansky B, Naccarelli GV, Kennedy JI Jr., Murphy EJ, Goldschlager N. 2015. Practical management guide for clinicians who treat patients with amiodarone. Am. J. Med. 129:468-75
27. Vorperian VR, Havighurst TC, Miller S, January CT. 1997. Adverse effects of low dose amiodarone: a meta-analysis. J. Am. Coll. Cardiol. 30:791-98
28. Gignoux E, Azman AS, de Smet M, Azuma P,Massaquoi M, et al. 2016. Effect of artesunate-amodiaquine on mortality related to Ebola virus disease. N. Engl. J. Med. 374:23-32
29. Deville-Bonne D, El Amri C, Meyer P, Chen Y, Agrofoglio LA, Janin J. 2010. Human and viral nucleoside/nucleotide kinases involved in antiviral drug activation: structural and catalytic properties. Antiviral Res. 86:101-20
30. Jordheim LP, Durantel D, Zoulim F, Dumontet C. 2013. Advances in the development of nucleoside and nucleotide analogues for cancer and viral diseases. Nat. Rev. Drug Discov. 12:447-64
31. Warren TK, Wells J, Panchal RG, Stuthman KS, Garza NL, et al. 2014. Protection against filovirus diseases by a novel broad-spectrum nucleoside analogue BCX4430. Nature 508:402-5
32. Biocryst Pharm. 2014. BioCryst announces study results for BCX4430 in a non-human primate model of Ebola virus infection. News Release, Dec. 23. Accessed on Mar. 20, 2016. http://investor.shareholder.com/biocryst/releasedetail.cfmReleaseID=888802
33. ClinicalTrials.gov. 2016. A Phase 1 study to evaluate the safety, tolerability and pharmacokinetics of BCX4430. NCT02319772, US Natl. Inst. Health, Bethesda,MD. https://clinicaltrials.gov/ct2/show/NCT02319772
34. Hostetler KY. 2010. Synthesis and early development of hexadecyloxypropylcidofovir: an oral antipoxvirus nucleoside phosphonate. Viruses 2:2213-25
35. Lanier R, Trost L, Tippin T, Lampert B, Robertson A, et al. 2010. Development of CMX001 for the treatment of poxvirus infections. Viruses 2:2740-62
36. Chimerix, Inc. 2014. Chimerix announces emergency investigational new drug applications for brincidofovir authorized by FDA for patients with Ebola virus disease. News Release, Oct. 6. Accessed on Oct. 11, 2015. http://ir.chimerix.com/releasedetail.cfmreleaseid=874647
37. McMullan LK, FlintM, Dyall J, Albarino C, Olinger GG, et al. 2016. The lipid moiety of brincidofovir is required for in vitro antiviral activity against Ebola virus. Antivir. Res. 125:71-78
38. ClinicalTrials.gov. 2016. Phase III, open-labeled, multicenter study of the safety and efficacy of brincidofovir (CMX001) in the treatment of early versus late adenovirus infection. NCT02087306, US Natl. Inst. Health, Bethesda, MD. http://clinicaltrials.gov/show/NCT02087306
39. Marty FM, Winston DJ, Rowley SD, Vance E, Papanicolaou GA, et al. 2013. CMX001 to prevent cytomegalovirus disease in hematopoietic-cell transplantation. N. Engl. J. Med. 369:1227-36
40. PainterW, Robertson A, Trost LC, Godkin S, Lampert B, Painter G. 2012. First pharmacokinetic and safety study in humans of the novel lipid antiviral conjugate CMX001, a broad-spectrum oral drug active against double-stranded DNA viruses. Antimicrob. Agents Chemother. 56:2726-34
41. Florescu DF, Kalil AC, Hewlett AL, Schuh AJ, Stroher U, et al. 2015. Administration of brincidofovir and convalescent plasma in a patient with Ebola virus disease. Clin. Infect. Dis. 61:969-73
42. Emory Healthc. 2014. Care of the Patient with Ebola Virus Disease. Atlanta: Emory Healthc. Accessed on Oct. 11, 2015. http://www.emoryhealthcare.org/ebola-protocol/pdf/overview-of-ebola.pdf
43. Cohen J,EnserinkM. 2016. As Ebola epidemic draws to a close, a thin scientific harvest. Science 351:12-13
44. Chimerix, Inc. 2015. Brincidofovir will not be considered in further clinical trials in Ebola virus disease. News Release, Jan. 30. Accessed on Oct. 11. http://ir.chimerix.com/releasedetail.cfmreleaseid=893927
45. Furuta Y, Takahashi K, Fukuda Y, Kuno M, Kamiyama T, et al. 2002. In vitro and in vivo activities of anti-influenza virus compound T-705. Antimicrob. Agents Chemother. 46:977-81
46. Baranovich T, Wong SS, Armstrong J, Marjuki H, Webby RJ, et al. 2013. T-705 (favipiravir) induces lethal mutagenesis in influenza A H1N1 viruses in vitro. J. Virol. 87:3741-51
47. Sangawa H, Komeno T, Nishikawa H, Yoshida A, Takahashi K, et al. 2013. Mechanism of action of T-705 ribosyl triphosphate against influenza virus RNA polymerase. Antimicrob. Agents Chemother. 57:5202-8
48. Caroline AL, Powell DS, Bethel LM, Oury TD, Reed DS, Hartman AL. 2014. Broad spectrum antiviral activity of favipiravir (T-705): protection from highly lethal inhalational Rift Valley Fever. PLOS Negl. Trop. Dis. 8:e2790
49. Gowen BB, Smee DF, Wong MH, Hall JO, Jung KH, et al. 2008. Treatment of late stage disease in a model of arenaviral hemorrhagic fever: T-705 efficacy and reduced toxicity suggests an alternative to ribavirin. PLOS ONE 3:e3725
50. Gowen BB, Wong MH, Jung KH, Sanders AB, Mendenhall M, et al. 2007. In vitro and in vivo activities of T-705 against arenavirus and bunyavirus infections. Antimicrob. Agents Chemother. 51:3168-76
51. Gowen BB, Wong MH, Jung KH, Smee DF,Morrey JD, Furuta Y. 2010. Efficacy of favipiravir (T-705) and T-1106 pyrazine derivatives in phlebovirus disease models. Antivir. Res. 86:121-27
52. Julander JG, Shafer K, Smee DF, Morrey JD, Furuta Y. 2009. Activity of T-705 in a hamster model of yellow fever virus infection in comparison with that of a chemically related compound, T-1106. Antimicrob. Agents Chemother. 53:202-9
53. Nyakatura EK, Frei JC, Lai JR. 2015. Chemical and structural aspects of Ebola virus entry inhibitors. ACS Infect. Dis. 1:42-52
54. Rocha-Pereira J, Jochmans D, Dallmeier K, Leyssen P, Nascimento MS, Neyts J. 2012. Favipiravir (T-705) inhibits in vitro norovirus replication. Biochem. Biophys. Res. Commun. 424:777-80
55. Smither SJ, Eastaugh LS, Steward JA, Nelson M, Lenk RP, Lever MS. 2014. Post-exposure efficacy of oral T-705 (favipiravir) against inhalational Ebola virus infection in a mouse model. Antivir. Res. 104:153-55
56. Oestereich L, Ludtke A, Wurr S, Rieger T, Munoz-Fontela C,Gunther S. 2014. Successful treatment of advanced Ebola virus infection with T-705 (favipiravir) in a small animal model. Antivir. Res. 105:17-21
57. Furuta Y, Gowen BB, Takahashi K, Shiraki K, Smee DF, Barnard DL. 2013. Favipiravir (T-705), a novel viral RNA polymerase inhibitor. Antivir. Res. 100:446-54
58. Cardile AP, Mayers DL, Bavari S. 2014. Current status of chemically synthesized inhibitors of Ebola virus. Recent Pat. Anti-Infect. Drug Discov. 9:97-103
59. Wolf T, Kann G, Becker S, Stephan C, Brodt HR, et al. 2015. Severe Ebola virus disease with vascular leakage and multiorgan failure: treatment of a patient in intensive care. Lancet 385:1428-35
60. Fujifilm Corp. 2014. AviganR-Tablet 200mg administered to a French woman infected with Ebola virus.News Release, Sept. 26. Accessed on Oct. 11, 2015. http://www.fujifilm.com/news/n140926.html
61. Varkey JB, Shantha JG, Crozier I, Kraft CS, Lyon GM, et al. 2015. Persistence of Ebola virus in ocular fluid during convalescence. N. Engl. J. Med. 372:2423-27
62. Mora-Rillo M, ArsuagaM,Ramirez-Olivencia G, de la Calle F, BorobiaAM, et al. 2015. Acute respiratory distress syndrome after convalescent plasma use: treatment of a patientwithEbola virus disease contracted in Madrid, Spain. Lancet Respir. Med. 3:554-62
63. Sissoko D, Laouenan C, Folkesson E,M'Lebing AB, Beavogui AH, et al. 2016. Experimental treatment with favipiravir for Ebola virus disease (the JIKI Trial): a historically controlled, single-arm proof-ofconcept trial in Guinea. PLOS Med. 13:e1001967
64. Sissoko D, Anglaret X, MalvyD. 2015. Favipiravir in patients with Ebola virus disease: early results of the JIKI trial in Guinea. Proc. Conf. Retrovir. Opportunistic Infect., Seattle, WA, Feb. 23-26, Abstr. 103-ALB
65. Mentré F, Taburet AM, Guedj J, Anglaret X, Këta S, et al. 2015. Dose regimen of favipiravir for Ebola virus disease. Lancet Infect. Dis. 15:150-51
66. Bouazza N, Treluyer JM, Foissac F, Mentré F, Taburet AM, et al. 2015. Favipiravir for children with Ebola. Lancet 385:603-4
67. Panel Antiretrovir. Guidel. Adults Adolesc. 2016. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Rep., Dep. Health Hum. Serv., Washington, D.C. Accessed on Mar. 2. http://aidsinfo.nih.gov/contentfiles/lvguidelines/AdultandAdolescentGL.pdf
68. Warren TK, Jordan R, Lo MK, Ray AS, Mackman RL, et al. 2016. Therapeutic efficacy of the small molecule GS-5734 against Ebola virus in rhesus monkeys. Nature 531:381-85
69. Gilead. 2016. Gilead Pipeline. Foster City, CA: Gilead. Accessed on Mar. 5. http://www.gilead.com/research/pipeline
70. Jacobs M, Rodger A, Bell DJ, Bhagani S, Cropley I, et al. 2016. Late Ebola virus relapse causing meningoencephalitis: a case report. Lancet 388:498-503
71. Farge E. 2015. Guinea's last Ebola case, a baby girl, leaves hospital. Reuters,Nov. 28. Accessed onMar. 5, 2016. http://www.reuters.com/article/us-health-ebola-guinea-idUSKBN0TH0PB20151128
72. Kole R, Krainer AR,Altman S. 2012.RNAtherapeutics: beyondRNAinterference and antisense oligonucleotides. Nat. Rev. Drug Discov. 11:125-40
73. Spurgers KB, Sharkey CM, Warfield KL, Bavari S. 2008. Oligonucleotide antiviral therapeutics: antisense and RNA interference for highly pathogenic RNA viruses. Antivir. Res. 78:26-36
74. Cullen BR. 2014. Viruses and RNA interference: issues and controversies. J. Virol. 88:12934-36
75. Friedrich BM, Trefry JC, Biggins JE, Hensley LE, Honko AN, et al. 2012. Potential vaccines and post-exposure treatments for filovirus infections. Viruses 4:1619-50
76. Torrecilla J, Rodŕguez-Gasc ón A, Solińs MA, del Pozo-Rodŕguez A. 2014. Lipid nanoparticles as carriers for RNAi against viral infections: current status and future perspectives. BioMed. Res. Int. 2014:161794
77. Geisbert TW, Lee AC, Robbins M, Geisbert JB, Honko AN, et al. 2010. Postexposure protection of non-human primates against a lethal Ebola virus challenge with RNA interference: a proof-of-concept study. Lancet 375:1896-905
78. Thi EP, Mire CE, Lee AC, Geisbert JB, Zhou JZ, et al. 2015. Lipid nanoparticle siRNA treatment of Ebola-virus-Makona-infected nonhuman primates. Nature 521:362-65
79. Iversen PL, WarrenTK, Wells JB,Garza NL,Mourich DV, et al. 2012. Discovery and early development of AVI-7537 and AVI-7288 for the treatment ofEbola virus andMarburg virus infections. Viruses 4:2806-30
80. Warren TK, Warfield KL, Wells J, Swenson DL, Donner KS, et al. 2010. Advanced antisense therapies for postexposure protection against lethal filovirus infections. Nat. Med. 16:991-94
81. Warren TK, Whitehouse CA, Wells J, Welch L, Heald AE, et al. 2015. A single phosphorodiamidate morpholino oligomer targeting VP24 protects rhesus monkeys against lethal Ebola virus infection. mBio 6:e02344-14
82. Kugelman JR, Sanchez-Lockhart M, Andersen KG, Gire S, Park DJ, et al. 2015. Evaluation of the potential impact of Ebola virus genomic drift on the efficacy of sequence-based candidate therapeutics. mBio 6:e02227-14
83. Shurtleff AC,Whitehouse CA, Ward MD, Cazares LH, Bavari S. 2015. Pre-symptomatic diagnosis and treatment of filovirus diseases. Front. Microbiol. 6:108
84. Heald AE, Iversen PL, Saoud JB, Sazani P, Charleston JS, et al. 2014. Safety and pharmacokinetic profiles of phosphorodiamidate morpholino oligomers with activity against Ebola virus and Marburg virus: results of two single-ascending-dose studies. Antimicrob. Agents Chemother. 58:6639-47
85. Dunning J, Sahr F, Rojek A, Gannon F, Carson G, et al. 2016. Experimental treatment of Ebola virus disease with TKM-130803: a single-arm Phase 2 clinical trial. PLOS Med 13:e1001997
86. Tekmira. 2015. Tekmira provides update on TKM-Ebola-Guinea. News Release, June 19. Accessed on July 23. http://investor.tekmirapharm.com/releasedetail.cfmReleaseID=918694
87. Tekmira. 2015. Tekmira announces launch of Arbutus Biopharma, a Hepatitis B solutions company. New Release, July 20. Accessed on Mar. 5, 2016. http://investor.arbutusbio.com/releasedetail.cfm ReleaseID=922758
88. Mupapa K, Massamba M, Kibadi K, Kuvula K, Bwaka A, et al. 1999. Treatment of Ebola hemorrhagic fever with blood transfusions from convalescent patients. J. Infect. Dis. 179(Suppl. 1):S18-23
89. Colebunders RL, Cannon RO. 2015. Large-scale convalescent blood and plasma transfusion therapy for Ebola virus disease. J. Infect. Dis. 211:1208-10
90. van Griensven J, Edwards T, de Lamballerie X, Semple MG, Gallian P, et al. 2016. Evaluation of convalescent plasma for Ebola virus disease in Guinea. N. Engl. J. Med. 374:33-42
91. Jahrling PB, Geisbert J, Swearengen JR, Jaax GP, Lewis T, et al. 1996. Passive immunization of Ebola virus-infected cynomolgus monkeys with immunoglobulin from hyperimmune horses. Arch. Virol. Suppl. 11:135-40
92. Jahrling PB, Geisbert JB, Swearengen JR, Larsen T, Geisbert TW. 2007. Ebola hemorrhagic fever: evaluation of passive immunotherapy in nonhuman primates. J. Infect. Dis. 196(Suppl. 2):S400-3
93. Jahrling PB, Geisbert TW, Geisbert JB, Swearengen JR, Bray M, et al. 1999. Evaluation of immune globulin and recombinant interferon-2b for treatment of experimental Ebola virus infections. J. Infect. Dis. 179(Suppl. 1):S224-34
94. Kudoyarova-Zubavichene NM, Sergeyev NN, Chepurnov AA, Netesov SV. 1999. Preparation and use of hyperimmune serum for prophylaxis and therapy of Ebola virus infections. J. Infect. Dis. 179(Suppl. 1):S218-23
95. Dye JM, Herbert AS, Kuehne AI, Barth JF, Muhammad MA, et al. 2012. Postexposure antibody prophylaxis protects nonhuman primates from filovirus disease. PNAS 109:5034-39
96. Lyon GM, Mehta AK, Varkey JB, Brantly K, Plyler L, et al. 2014. Clinical care of two patients with Ebola virus disease in the United States. N. Engl. J. Med. 371:2402-9
97. Qiu X, Wong G, Audet J, Bello A, Fernando L, et al. 2014. Reversion of advanced Ebola virus disease in nonhuman primates with ZMapp. Nature 514:47-53
98. Mendoza EJ, Qiu X, Kobinger GP. 2016. Progression of Ebola therapeutics during the 2014-2015 outbreak. Trends Mol. Med. 22:164-73
99. Davey R. 2016. PREVAIL II: a randomized controlled trial of ZMappTM in acute Ebola virus infection. Webcast, CROI, Feb. 22-25. Accessed on Mar. 10. http://www.croiwebcasts.org/console/player/29572mediaType=audio&
100. Corti D, Misasi J, Mulangu S, Stanley DA, Kanekiyo M, et al. 2016. Protective monotherapy against lethal Ebola virus infection by a potently neutralizing antibody. Science 351:1339-42
101. Holtsberg FW, Shulenin S, Vu H, Howell KA, Patel SJ, et al. 2015. Pan-ebolavirus and pan-filovirus mouse monoclonal antibodies: protection against Ebola and Sudan viruses. J. Virol. 90:266-78
102. Furuyama W, Marzi A, Nanbo A, Haddock E, Maruyama J, et al. 2016. Discovery of an antibody for pan-ebolavirus therapy. Sci. Rep. 6:20514
103. Howell KA, Qiu X, Brannan JM, Bryan C, Davidson E, et al. 2016. Antibody treatment of Ebola and Sudan virus infection via a uniquely exposed epitope within the glycoprotein receptor-binding site. Cell Rep. 15:1514-26
104. Qiu X, Audet J, Lv M, He S, Wong G, et al. 2016. Two-mAb cocktail protects macaques against the Makona variant of Ebola virus. Sci. Transl. Med. 8:329ra33
105. Smith LM, Hensley LE, Geisbert TW, Johnson J, Stossel A, et al. 2013. Interferon-therapy prolongs survival in rhesus macaque models of Ebola and Marburg hemorrhagic fever. J. Infect. Dis. 208:310-18
106. Adebamowo C, Bah-Sow O, Binka F, Bruzzone R, Caplan A, et al. 2014. Randomised controlled trials for Ebola: practical and ethical issues. Lancet 384:1423-24
107. Pres. Comm. Study Bioethical Issues. 2015. Ethics and Ebola: Public Health Planning and Response. Rep., Pres. Comm. Study Bioethical Issues, Washington, DC. Accessed on Mar. 20, 2016. http://bioethics. gov/sites/default/files/Ethics-and-Ebola-PCSBI-508.pdf
108. Dodd LE, Proschan MA, Neuhaus J, Koopmeiners JS, Neaton J, et al. 2016. Design of a randomized controlled trial for Ebola virus disease medical countermeasures: PREVAIL II, the Ebola MCM study. J. Infect. Dis. 213:1906-13